Below you'll find a list of all posts that have been tagged as “orphan drug”
Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …
We’re excited to announce that Raul Vivar, General Director of Shire Mexico, will be speaking at this year’s BioPharma Mexico. Raul’s presentation is titled “Accessing public institutions: A success story changing the lives of lysosomal disease patients”, and will take place at 4:05 pm on Wednesday, November 5th. Don’t miss it! Download our interview with Raul here During his presentation, …
Es un placer contar con la participacion de David López, Country Manager México de BioMarin Pharmaceutical, como uno de nuestros ponentes en BioPharma México 2014. Tuvimos el placer de entrevistar a David antes del evento y le preguntamos varias cuestiones sobre el estatus de las enfermedades raras en México que te darán una mejor idea de cómo funciona la industria. …
In the Pharmaceutical and Biotech industries, partnering and collaborations are a frequent occurrence. Usually, a larger company will utilize a more niche company as a partner for a specific function (CROs and CMOs), or find a smaller drug discovery company that has a compound of interest. This is particularly true in the Orphan Drug industry, where small pharma companies are …
BioPharma Mexico is only a few months away, and we’re excited to see you there along with the rest of the Mexican biopharma industry. There’s been a great response so far, with the number of attendees growing every day. Now available is a sample of the attendee list to show you some of the great pharma, biotech, and advocacy groups …
Orsini Healthcare is a leading national specialty pharmacy focused on the delivery of specialty medications to patients with rare conditions. Their disease-specific clinical CareTeam programs, commitment to high-touch customer service, and our patient centered approach ensures satisfaction and adherence to treatment. Orsini Healthcare will be exhibiting at this year’s World Orphan Drug Congress USA, and we were lucky enough to …
Orphan drug development is often perceived as being done by small biotech companies. However, most big pharmaceutical companies are heavily invested in the rare disease community. In this exclusive interview with Rare Disease Report, Bert Bruce, Vice President of Rare Disease Commercial Development at Pfizer Inc, previews his presentation at the upcoming World Orphan Drug Congress USA 2014 being held …
The European Medicines Agency (EMA) and Australia’s Therapeutic Goods Administration (TGA) have announced, at a collaboration meeting in London, that they are to share the full assessment reports related to marketing authorisations (MA) for orphan drugs. According to EMA executive director Professor Guido Rasi and Professor John Skerritt, national manager of the TGA, this will lead to greater scientific exchange when …
Highlights of the event and interviews with key industry people at the conference will be aired in The Balancing Act's rare disease segment on August 1 and 8. Don't miss this special feature! Tune in to the Lifetime Channel at 7am next two Thursdays. Many don't realize there is a daily television segment focused on rare diseases. It's shorter than …
Differently from the uncertainty of the economic growth across developed countries, the pharmaceutical industry is optimistic about the increasing revenue from orphan drug development. In a recent report conducted by BCC Research, the orphan drug market in 2012 was evaluated in $82 billion and is expected to grow at an average rate of 5.4% in the next five years, to …